Activation of TLR–TRAF6 signaling by chronic inflammation in myelodysplastic syndromes increases the competitive advantage of HSPCs harboring MDS mutations through the upregulation of the ubiquitin-modifying enzyme A20 and a switch from canonical to non-canonical NF-κB signaling.
References
Muto, T. et al. Nat. Immunol. https://doi.org/10.1038/s41590-020-0663-z (2020).
Barreyro, L., Chlon, T. M. & Starczynowski, D. T. Blood 132, 1553–1560 (2018).
Will, B. et al. Blood 120, 2076–2086 (2012).
Chen, J. et al. Nat. Med. 25, 103–110 (2019).
Will, B. et al. Nat. Med. 21, 1172–1181 (2015).
Sperling, A. S., Gibson, C. J. & Ebert, B. L. Nat. Rev. Cancer 17, 5–19 (2017).
Muto, T. et al. J. Exp. Med. 210, 2627–2639 (2013).
Fang, J. et al. Nat. Immunol. 18, 236–245 (2017).
Nilsson, L. et al. Blood 100, 259–267 (2002).
Thanopoulou, E. et al. Blood 103, 4285–4293 (2004).
Yamaguchi, N., Oyama, M., Kozuka-Hata, H. & Inoue, J. Sci. Rep. 3, 2568 (2013).
Bird, L. Nat. Rev. Immunol. 15, 598 (2015).
Papa, S. et al. Cell Death Differ. 13, 712–729 (2006).
Pellagatti, A. et al. Leukemia 24, 756–764 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Ueda, K., Kumari, R. & Steidl, U. Fueling clonal dominance through TRAFficking of NF-κB signaling. Nat Immunol 21, 489–490 (2020). https://doi.org/10.1038/s41590-020-0662-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-020-0662-0
- Springer Nature America, Inc.